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Abstract 41 
Acute kidney injury (AKI) is common following paraquat ingestion. The diagnostic performance of injury 42 
biomarkers was investigated in serial blood and urine samples from patients from 5 Sri Lankan hospitals. Functional 43 
AKI was diagnosed using serum Creatinine (sCr) or serum cystatin C (sCysC). The 95th centile in healthy subjects 44 
defined the urinary biomarker cutoffs for diagnosing structural AKI. 50 poisoned patients provided 2 or more 45 
specimens, 76% developed functional AKI [AKIN stage 1 (n=12), 2 (n=7) or 3 (n=19)]; 19/26 patients with AKIN 46 
stage 2/3 also had functional AKI by sCysC criteria (≥50% increase).  Urinary cystatin C (uCysC), clusterin (uClu) 47 
and NGAL (uNGAL) increased within 24 hours of ingestion compared with NoAKI patients and healthy controls. 48 
Each biomarker demonstrated moderate diagnostic utility [AUC-ROC: uCysC 0.79, uNGAL 0.79, uClu 0.68] for 49 
diagnosis of functional AKI at 16 hours. Death occurred only in subjects with functional AKI. Structural biomarker-50 
based definitions detected more AKI than did sCr or sCysC, but did not independently predict death. Renal injury 51 
biomarkers did not add clinical value to patients who died rapidly due to multi-organ failure. Use of injury biomarkers 52 
within 16-24 hours may guide early intervention for reno-protection in less severe paraquat poisoning.  53 
 54 
1. Introduction 55 
Deliberate self-poisoning with paraquat herbicide is common and has an estimated case fatality of more than 50% 56 
(Dawson et al., 2010), particularly when followed by acute kidney injury (AKI) (Kim et al., 2009; Lee et al., 2002). 57 
Paraquat-induced oxidative stress in the acute phase leads to toxicity in many organs particularly lungs and kidneys 58 
(Dinis-Oliveira et al., 2008; Gawarammana and Buckley, 2011) while paraquat induced AKI may aggravate toxicity 59 
to other organs by decreasing paraquat clearance (Beebeejaun et al., 1971). 60 
 61 
Several studies have shown that the rapid increase in sCr following paraquat poisoning (Gil et al., 2009; Roberts et 62 
al., 2011) cannot be solely driven by the AKI-mediated decrease in glomerular filtration rate (GFR) and hence over-63 
estimates true renal functional loss (Fahim et al., 2013). Therefore, alternative approaches would be useful for early 64 
diagnosis or confirmation of paraquat-induced nephrotoxicity. A panel of seven biomarkers proposed by the 65 
Predictive Safety Testing Consortium (PSTC) was qualified by the Food and Drug Administration (FDA) and 66 
European Medicines Agency (EMEA) for safety assessment in pre-clinical drug development studies (Dieterle et al., 67 
2010; Ferguson et al., 2008). These diagnose AKI early with high specificity and sensitivity depending upon site and 68 
mode of renal injury (Bonventre et al., 2010).  69 
 70 
The clinical utility of most novel urinary biomarkers in detecting AKI has not been explored after paraquat poisoning. 71 
A few small clinical studies have utilised serum cystatin C (sCysC), urinary kidney injury molecule-1 (uKIM-1), 72 
plasma (pNGAL) (neutrophil gelatinase-associated lipocalin) and urinary NGAL (uNGAL) to predict death (Roberts 73 
et al., 2011) and in one study to diagnose AKI, where increases in sCr preceded increases in uNGAL and uKIM-1 74 
(Gil et al., 2009).  In contrast,  urinary KIM-1, urinary cystatin C (uCysC) and albumin (uAlb) were sensitive 75 
biomarkers in predicting paraquat-induced AKI within 16-24 hours in a nephrotoxic rat model as defined by 76 
histopathological change (Wunnapuk et al., 2013). In order to determine the clinical utility of injury biomarkers, we 77 
performed frequent serial biomarker measurements in a prospective patient cohort following paraquat poisoning, 78 
utilising the FDA/EMEA qualified panel of biomarkers plus additional selected novel urinary damage biomarkers.  79 
 80 
We hypothesized that a panel of novel urinary structural damage biomarkers are superior to serum creatinine in 81 
independently detecting paraquat-induced nephrotoxic AKI (ToxAKI) and correlate with specific pathways of renal 82 
injury. The main objective of this study is to evaluate the utility of PSTC biomarkers panel and additional selected 83 
urinary biomarkers in early diagnosis of paraquat-induced ToxAKI and to explore whether increase in specific 84 
biomarker relate to mechanism-specific injury pathways. The other aim of this study is to evaluate whether pre-85 
clinical paraquat ToxAKI rodent model findings translate into clinical practice. 86 
2. Methods 87 
2.1 Study design and data collection  88 
This nested cohort study within an ongoing multi-centre observational study on self-poisoning in Sri Lanka was 89 
approved by the human research ethics committees of both the University of New South Wales (Sydney), Australia 90 
and the University of Peradeniya (Peradeniya, Sri Lanka). Between October 2010 and March 2013, patients admitted 91 
to study hospitals within 24 hours of paraquat ingestion were consented after initial resuscitation and clinical 92 
management using written informed consent from each patient or a relative. Patients who were < 15 years, pregnant, 93 
had co-ingested other toxins, or unable to provide samples were excluded. Paraquat ingestion was confirmed by a 94 
positive urine dithionate test. Demographic and clinical data were collected from consenting patients until discharge.  95 
2.2 Sample collection and biomarker assays 96 
Blood and urine samples were collected at 4, 8, 16 and 24 hours after ingestion where possible, then daily until 97 
discharge or death and at follow-up at one and three months. Blood and urine samples were also collected from 98 
consenting healthy volunteers to establish normal baseline biomarker concentrations. All samples were processed 99 
within 30 minutes of collection. Blood samples were spun at 2000-3000 rpm and serum samples were transferred in 100 
to small cryotubes. Urine samples were immediately centrifuged at 1500-2000 rpm and the supernatant stored. Both 101 
serum and urine aliquots were stored at -20°C  for up to 3 months and then -70°C until batch analysis within 6 months. 102 
 103 
Biomarker assays were conducted batch-wise on samples collected from both patients and healthy controls. Serum 104 
and urine creatinine were measured using the Jaffe method (kinetic method, rate blank and compensated) on a Hitachi 105 
912 automatic analyser (Roche, Japan). Serum CysC was quantified using microparticle enhanced 106 
immunoturbidimetry on a clinical chemistry analyser (KonelabTM, Thermo Fisher, Waltham, MA) following the 107 
manufacturer’s recommendations.  108 
 109 
DuoSet ELISA kits (R&D systems®) were used to assay uKIM-1, and uClu. Urinary IL-18 was measured using the 110 
platinum enzyme-linked immunosorbent assay (Bender MedSystems, Vienna, Austria). Intra- and inter-assay 111 
precision for ELISA was <10%. Six AKI biomarkers [uCysC, uAlb, urinary trefoil factor 3 (uTFF3), osteopontin 112 
(uOstP), beta-2-microglobulin (uβ2M) and uNGAL] were quantified simultaneously using Bio-Plex Pro™ RBM 113 
Human Kidney Toxicity Assays panel 2 on the Bio-Plex 200 system (BIO-RAD, USA). Inter- and intra-assay 114 
precision was <15% and <5% respectively. Serum and urinary paraquat levels were measured at the Therapeutic 115 
Research Centre, University of Queensland, Brisbane, Australia, using LC–MS/MS (Wunnapuk et al., 2011). 116 
Biomarker concentrations were reported as the absolute concentration or normalised to uCr excretion (Ralib et al., 117 
2012; Westhuyzen et al., 2003). The area under the concentration curve (24hrAUC, a measure of the biomarker 118 
concentration integrated over time) at 24 hours for each biomarker was calculated using the trapezoidal rule. Apparent 119 
creatinine clearance was calculated in ml/min from: [urine flow rate (ml/min) * uCr (mg/dl)) / sCr]. 120 
2.3 Outcome measurement 121 
Functional AKI was defined by two approaches based either on an increase in sCr or sCysC. Diagnostic performance 122 
of each urinary biomarker was assessed using both these definitions and compared in sensitivity analysis. Acute 123 
Kidney Injury Network (AKIN) criteria were used to define functional AKI based on sCr (Mehta et al., 2007) and to 124 
categorise patients into severity stages. Despite noted limitations of sCr, AKIN definition was used in this study since 125 
it is widely used definition to assess the performance of novel injury biomarkers in clinical studies (Siew et al., 2011; 126 
Waikar et al., 2012). Further, clinical biomarker studies have used different percentage change in sCr or sCysC to 127 
define functional AKI (Briguori et al., 2010; Nejat et al., 2010; Pickering and Endre, 2014; Siew et al., 2011; Waikar 128 
et al., 2012). Therefore, development of moderate or severe AKI (stage 2 or 3, an increase in sCr of ≥200% or 300% 129 
respectively) was selected as the primary outcome definition (Basu et al., 2014) of functional AKI in this cohort since 130 
rapid increases in serum creatinine within 24 hours of paraquat ingestion does not represent true renal functional loss 131 
(Mohamed et al., 2015). Alternatively, a 50% or greater increase in sCysC (Nejat et al., 2010) was used to diagnose 132 
functional AKI. Ideally, these definitions require a baseline level obtained within the three months prior to renal 133 
injury (Bellomo et al., 2004; KDIGO, 2012), a parameter not available in any of our patients as in many other research 134 
and hospital settings (Gaiao and Cruz, 2010; Hoste et al., 2006). Therefore, we used the lowest sCr or sCysC value 135 
in survivors measured prior to hospital discharge or at follow-up (Chertow et al., 2005; Endre et al., 2010; Lopes et 136 
al., 2008) and the  MDRD75 (Bellomo et al., 2004; Gaiao and Cruz, 2010; Hoste et al., 2006; KDIGO, 2012) and 137 
CKD-EPI75 equations (Inker et al., 2012) to estimate baseline sCr and sCysC in non-survivors if these were lower 138 
than the measured lowest value.  139 
 140 
Defining AKI based on structural (damage) and/or functional biomarker concentrations has been proposed recently 141 
(Murray et al., 2014), although with different approaches to define biomarker cutoff values (Basu et al., 2014; 142 
Pickering and Endre, 2013a, b). Defining AKI based on structural biomarkers may be useful in clinical conditions 143 
where sCr based definition may not be appropriate. We defined structural-AKI when structural damage biomarker 144 
concentration exceeded the 95th centile of the biomarker concentrations in healthy volunteers from a population with 145 
similar demographic characteristics to the patients (Basu et al., 2014). Similar approaches using healthy reference 146 
cutoff values have commonly been used for diagnosis and risk stratification of myocardial injury, utilising cardiac 147 
troponin (Alpert et al., 2000; Morrow et al., 2007). 148 
2.4 Statistical Analysis  149 
Biomarker concentrations were compared with those in healthy controls to identify renal injury at each time point. 150 
The time course for each biomarker was assessed graphically. Continuous and categorical variables were summarised 151 
using median and interquartile range, or mean ± standard error of mean (SEM), and proportions respectively. The 152 
data were compared using the Wilcoxon rank sum and Kruskal-Wallis tests for continuous variables and Fisher’s 153 
exact test for categorical variables. The Spearman coefficient was used to estimate the correlation between 154 
biomarkers. The diagnostic performance of each biomarker at each time point, and the peak biomarker concentration 155 
within 24 hours of ingestion were evaluated by area under the receiver operator characteristic curve (AUC-ROC) and 156 
compared with healthy subject or no-AKI patients as controls. The optimal threshold for each biomarker was selected 157 
based on the Youden index, the cutoff value with the maximum sum of specificity and sensitivity. Statistical analyses 158 
were conducted using GraphPad Prism version 6 (GraphPad Software, San Diego, USA) and STATA IC10 159 
(StataCorp, 2007, TX, USA). 160 
 161 
3 Results 162 
3.1 Patient recruitment 163 
Eighty-five patients with a history of paraquat self-poisoning were admitted to the study hospitals. Four patients 164 
declined to participate (Fig. 1). Since diagnosis of AKI using the AKIN or KDIGO criteria requires at least two sCr 165 
measurements, patients were divided into two groups based on the number of samples available: a cross-sectional 166 
and a longitudinal (main) cohort. The cross-sectional cohort (CSC) comprised patients with fewer than two blood 167 
and/or urine samples within first 7 days after paraquat ingestion (n=31). Patients who provided at least two blood 168 
and urine samples formed the main cohort (n=50) (Fig. 1). 169 
 170 
Fig. 1. Patient recruitment profile 171 
† Cross sectional cohort; these patients consented and provided only one blood and/or urine sample within first 7 172 
days. Of 31 patients in this group, 10 patients died within 48 hours. ‡ All patients in this group provided at least two 173 
blood and urine samples and considered for the main analysis. 174 
 175 
3.2 Longitudinal (main) cohort: AKI and baseline characteristics  176 
Twenty four patients (48%) demonstrated an increase in sCr < 100% (NoAKI=12, AKIN stage 1 =12) while 26 (52%) 177 
increased ≥100% (AKIN stage 2, n=7, or stage 3, n=19) (Fig. 1). Baseline characteristics were similar between these 178 
Total number of patients 
admitted (n=85)
Consented
(n=81)
Eligible patients for 
biomarker analysis 
(n=50) ‡
AKIN 2 & 3
(n= 26, 52%)
Survivors
(n=14, 54%)
Non-survivors
(n=12, 46%)
AKIN 0 & 1
(n=24, 48%)
Non-survivors 
(n=0)
Survivors
(n=24, 100%)
Consent declined 
(n=4, 1 died) 
 
Cross sectional 
cohort  
(n=31, 10 died) † 
two groups except for sCr and maximum 24 hour serum paraquat levels. The latter were higher (p<0.001) for patients 179 
with a sCr increase ≥100% (Table 1) as seen in a different paraquat poisoning cohort (Weng et al., 2012). Twelve of 180 
26 patients who had sCr increase ≥100% died, while no patients with increase <100% died (p=0.0001). 181 
 182 
Table 1. Baseline demographic and clinical characteristics 183 
Baseline characteristics  No-AKI & AKIN1  
(n=24) 
AKIN 2/3 
(n=26) 
p 
Age (years) 25 (19-34) 25 (19-32) 0.77 
Male gender (%) 58 % 50% 0.74 
Weight (kg) 50 (45-59) 50 (40-58) 0.92 
Amount ingested (ml) 20 (10-45) 20 (20-50) 0.08 
Time to admission (hours) 4 (1-6) 3.5 (2-9) 0.37 
Pulse (beats/minutes) 88 (80-88) 80 (76-87) 0.21 
BP systolic (mm Hg) 110 (110-120) 115 (110-120) 0.88 
BP diastolic 70 (70-80) 75 (70-80) 0.93 
sCysC (mg/l) 0.7 (0.6-0.8) 0.7 (0.6-0.9) 0.56 
sCr (mg/dl) 0.73 (0.66-0.87) 1.03 (0.55-1.40) 0.03 
24 hour maximum serum- 
paraquat levels (ng/ml) 
21 (10-212) 663 (97-1430) 0.0004 
Fatal outcome 0 12 (46%) 0.0001 
Number of patients with ≥50 % 
relative increase in sCysC (n) 
0 19 (74%) ‡ - 
Results are shown as median (Inter quartile range) or n (%). ‡ There were 7 patients who had a relative increase of 184 
sCr ≥ 100% but less than 50% increase in sCysC, 3 were diagnosed as AKIN stage 2 and 4 were AKIN stage 3.   185 
An increase of ≥50% in sCysC was seen only in patients with a relative rise in sCr of ≥100% [(n=19, 10 deaths), 186 
Table 1, Fig. 2]. Among 31 patients (death, n=2) with <50% increase in sCysC, 19 had functional AKI by sCr 187 
definition. Increases in sCr occurred earlier in these patients (within 8 hours) compared to sCysC (by 16 hours) (Fig. 188 
2a). In contrast, when lesser increases in both functional biomarkers were observed (sCr <100% and sCysC <50%), 189 
both analytes were increased by 16 hours (Fig. 2b).  190 
 191 
Fig. 2. Temporal profile of relative changes in sCr and sCysC in paraquat poisoning 192 
Relative changes (mean ± SEM) of sCr (black circles) and sCysC (blue squares) are shown. Relative changes in sCr 193 
occurred earlier than sCysC when a relative change in sCr was > 50%. Serum Cr continued to increase in severe 194 
poisoning while sCysC peaked between 24-48 hours and then reached a new steady state. Panel (a) sCr ≥100% & 195 
sCysC≥50%; (b) sCr≥50 % but < 100% and sCysC<50% (c) both sCr and sCysC <50% 196 
 197 
3.3 Biomarkers in the cross sectional and main cohort  198 
Biomarker concentrations measured at 16 hours in the main cohort and maximum biomarker concentrations in 199 
patients from the cross sectional cohort [median age 28 (IQR 19-44) years] are shown in Supplementary Fig1. 200 
Although biomarker concentrations in most cross sectional cohort patients were similar to patients in the main cohort, 201 
very elevated levels were seen in some non-survivors.  202 
 203 
3.4 Urinary biomarker profiles in the main cohort 204 
Both absolute and normalised concentrations of uCysC, uClu and uNGAL increased to above the 75th centile (of 205 
healthy control values) in patients who developed AKI stage 2 or 3, while concentrations remained low in patients 206 
who didn’t develop AKI or had mild AKIN stage 1 (Fig. 3). Normalisation of uCysC, uClu, uNGAL and particularly 207 
uKIM-1 to uCr better separated the AKIN 2/3 group from patients who didn’t develop AKI (Fig. 3). At 16-24 hours, 208 
uCysC, uClu and uNGAL were significantly increased (p<0.01) compared to healthy controls or no-AKI patient 209 
controls (Fig. 3).  210 
 211 
Fig. 3. Biomarker concentration (normalised to urinary creatinine) profiles following paraquat poisoning 212 
Individual patient’s absolute concentrations of sCr, sCysC and normalised biomarker concentrations of uCysC, uClu, uKIM-1 and uNGAL are shown (dashed lines). Blue 213 
dashed lines depict patients who developed AKIN stage 2 and other patients in this group represent AKIN stage 3. The dark bolded line in each graph represents the median 214 
(± IQR) change in each group (green line-No-AKI group; purple line-AKIN stage 1 group, red line-AKI≥2 group). The grey shaded area illustrates the normal range based 215 
on respective biomarkers measured in healthy individuals (dark grey area-5th to 75th centiles; light grey area-75th to 95th centiles of the normal range). 216 
In contrast, concentrations of several other biomarkers (uAlb, uβ2M, uIL-18, uTFF3 and uOstP) were not markedly 217 
increased and did not distinguish between the two groups. Urinary albumin increased in all patients regardless of 218 
AKI (Supplementary Fig. 2). Time-course of absolute urinary biomarker concentrations are presented in 219 
Supplementary Figs 3 and 4.  220 
 221 
3.5 Twenty four hour peak biomarker concentrations (24hrMax) and 24hrAUC  222 
Both absolute and normalised 24hr peak concentrations of uCysC, uClu and uNGAL in patients who developed 223 
AKIN stage 2 or 3 were higher (normalised uCysC, p<0.0001, uClu, p<0.0005, uNGAL, p< 0.005) and correlated 224 
with AKI severity (Supplementary Fig. 5). The total area under the biomarker concentration curve over 24 hours 225 
(24hrAUC, 24hr total biomarker excretion which is a measure of the biomarker concentration integrated over time) 226 
for each biomarker was also higher in patients who developed AKIN 2/3 (normalised uCysC, p<0.005, uClu, p<0.01, 227 
uNGAL, p< 0.05). The gradients observed between the normalised urinary biomarker increases and the maximum 228 
sCr increases are a measure of the enhancement resulting from normalisation to urinary creatinine. Normalisation 229 
has enhanced urinary biomarker diagnostic performance in each case illustrated (Supplementary Fig. 5).  230 
 231 
3.6 Structural and functional AKI 232 
The time course profiles of structural damage biomarkers exhibited increase within the first 24 hours with the duration 233 
of uNGAL increase was being the briefest of these biomarkers (Fig. 4). The 95th centile biomarker concentrations in 234 
sixty-three healthy Sri Lankan volunteers [median age 28 years (IQR: 26-33), 70% male] used to define structural-235 
AKI, were uCysC: 70 ng/mg Cr; uClu: 420 ng/mg Cr; and uNGAL: 120 ng/mg Cr. Table 2 summarises 24 hour peak 236 
concentrations of urinary biomarkers and serum paraquat in patients with or without functional or structural AKI as 237 
per recently proposed AKI definition matrix (Murray et al., 2014). Patients who were structural biomarker positive 238 
based on uCysC or uClu definition but functional negative had similar (Table 2 a) or even higher (Table 2 b) serum 239 
paraquat concentration compare to patients who had functional AKI but no structural AKI. 240 
 241 
 242 
Fig. 4 Biomarker time courses according to definition as functional or structural or combined functional and 243 
structural AKI 244 
In contrast to the other structural markers, the time course of uNGAL appears brief, while those of uCysC and uClu 245 
remain increased for at least 48 hours. The lines are represented as follows; No functional and no structural AKI 246 
(black), Functional AKI but no structural AKI (blue), Structural AKI but no functional AKI (green), Both functional 247 
and structural AKI (red). Sample volume collected was not sufficient in one patient for quantifying uNGAL and 248 
uCysC using the Bioplex assays and hence only uClu was measured. Serum creatinine ≥ 100% (AKI≥2) is defined as 249 
functional AKI while biomarker concentration >95th centile value in healthy volunteers (uCysC: 70 ng/mg Cr; uClu: 250 
420 ng/mg Cr; and uNGAL: 120 ng/mg Cr) were used to define structural AKI. Each cell in the matrix displays 251 
number of patients with number of deaths inside parenthesis. 252 
 253 
 254 
 255 
Table 2 Peak urinary biomarker and serum creatinine concentrations in patients with or without functional and 256 
structural AKI  257 
(a) uCysC definition  258 
 
 
 
No structural-AKI Structural-AKI 
 
No functional-AKI 
 
B 26 (2-50) 
P 13 (10-21) 
[n=15, 31%] 
 
B 135 (97-206) 
P 398 (84-750) 
[n=8, 16%] 
 
Functional-AKI 
 
B 23 (13-38) 
P 461 (62-1076) 
[n=4, 8%)] 
 
B 446 (26-782) 
P 663 (276-3700) 
[n=22, 45%] 
 259 
(b) uClu definition 260 
 
 
 
No structural-AKI Structural-AKI 
 
No functional-AKI 
 
B 90 (45-160) 
P 16 (10-22) 
[n=19, 38%] 
 
B 1457 (1048-4546) 
P 574 (398-750) 
[n=5, 10%] 
 
Functional-AKI 
 
B 94 (21-216) 
P 90 (89-767) 
[n=5, 10%] 
 
B 2337(1212-6298) 
P 992 (498-3700) 
[n=21, 42%] 
 261 
(c) uNGAL definition 262 
 
 
 
No structural-AKI Structural-AKI 
 
No functional-AKI 
 
B 33 (21-48) 
P 13 (11-116) 
[n=20, 41%] 
 
B 220 (122-221) 
P 84 (21-398) 
[n=3, 6%] 
 
Functional-AKI 
 
B 61 (32-84) 
P 832 (276-3700) 
[n=14, 29%] 
 
B 390 (190-706) 
P 555 (90-767) 
[n=12, 24%] 
Definitions: Functional-AKI: AKIN stage 2/3 (≥100% increase in sCr), Structural AKI: uCysC > 70 ng/mg Cr or 263 
uClu > 420 ng/mg Cr or uNGAL 120 ng/mg Cr.  Normalised peak concentrations (in ng/mg Cr) were attained within 264 
24 hours of admission. Biomarker value (first row in each cell represented as ‘B’) and serum paraquat (ng/ml) 265 
concentrations (second row in each cell represented as ‘P’) are presented as median (Inter quartile range). Number 266 
of patients under each spectrum of AKI combination is presented inside parenthesis (third row in each cell). 267 
 268 
Overall 65% of subjects diagnosed with structural AKI with at least one of these biomarkers (Fig. 5) while uCysC 269 
diagnosed the most patients (n=30). Structural-AKI diagnosed by uCysC, uClu and uNGAL occurred in 16% (n=8), 270 
10% (n=5) and 6% (n=3) respectively of patients not diagnosed AKI by changes in sCr ≥100% (Table 2, Figs. 4 & 271 
5). The combination of uClu and uCysC appeared best and diagnosed all but 3 patients who developed functional 272 
AKI (Fig. 5 b & f).  273 
 274 
The same biomarker cutoffs were evaluated to determine the sensitivity and specificity for AKI and death (Table 3).  275 
Urinary CysC had good sensitivity for death (0.92), whereas uNGAL was poor (0.58). However, death occurred only 276 
in subjects with functional AKI [AKIN stage 2/3 (e-h) or >50% increase in sCysC (a-d)] or both functional and 277 
structural AKI (Fig. 4 & 5). Using other cutoffs (97.5th or 99th centile) of normal biomarker concentrations did not 278 
influence these observations.  At 24 hours, sCr revealed an excellent AUC-ROC profile [0.95 (95% CI 0.9-1] to 279 
predict death while sCysC also produced a good prognostic performance [0.8 (0.7-1)]. 280 
  281 
 282 
 283 
Fig. 5 AKI classification according to combination of two or more structural biomarkers 284 
More patients developed structural AKI when uCysC and uClu concentrations were above the cut-off values used for 285 
defining structural AKI. Structural AKI is defined as biomarker concentrations > 95th centiles values obtained from 286 
the healthy volunteers (uCysC: 70 ng/mg Cr; uClu: 420 ng/mg Cr; and uNGAL: 120 ng/mg Cr). Functional AKI in 287 
matrix (a-d) is defined as ≥ 50% increase in sCysC and in matrix (e-h) is based on AKIN definition. Each cell displays 288 
number of patients with number of deaths inside parenthesis. (-): structural biomarkers negative, (+): one structural 289 
biomarker positive. (++): two structural biomarkers positive, (+++): three structural biomarkers positive. 290 
Table 3 Sensitivity and specificity for functional AKI or death based on structural biomarker thresholds 291 
Biomarkers cut-off‡ and 
outcome 
Sensitivity Specificity Positive likelihood 
ratio  
Negative likelihood 
ratio 
Diagnostic odds ratio 
uCysC (>70 ng/mg Cr) 
Functional-AKI 
Death 
 
0.85 (0.66-0.94) 
0.92 (0.65-0.98) 
 
0.65 (0.45-0.81) 
0.49 (0.33-0.64) 
 
2.43 (1.36-4.36) 
1.79 (1.25-2.55) 
 
0.24 (0.09-0.61) 
0.17 (0.02-1.15) 
 
10.31 (2.63-40.5) 
10.42 (1.22-89.13) 
uClu (>420 ng/mg Cr) 
Functional-AKI 
Death 
 
0.81 (0.62-0.91) 
0.83 (0.55-0.95) 
 
0.79 (0.60-0.91) 
0.58 (0.42-0.72) 
 
3.88 (0.60-0.91) 
1.98 (1.26-3.10) 
 
0.24 (0.11-0.55) 
0.29 (0.08-1.05) 
 
15.96 (3.99-63.84) 
6.88 (1.32-35.77) 
uNGAL (>120 ng/mg Cr) 
Functional-AKI 
Death 
 
0.46 (0.29-0.65) 
0.58 (0.32-0.81) 
 
0.87 (0.68-0.95) 
0.78 (0.63-0.0.89) 
 
3.54 (1.14-11.0) 
2.7 (1.24-5.87) 
 
0.62 (0.42-0.91) 
0.53 (0.27-1.06) 
 
5.71 (1.36-20.06) 
5.08 (1.26-20.36) 
Functional AKI: AKIN stage 2/3 (≥100 increase in sCr), ‡ cut-offs are 95th centile values obtained from healthy volunteer data. 292 
  293 
3.7 Correlation of functional and structural biomarkers and among injury biomarkers 294 
A positive correlation (r ≥0.5) was observed between sCr and the structural biomarkers, uCysC, uClu and 295 
uNGAL, 16 hours post ingestion. The correlation with sCysC was notably poor. As expected, the apparent 24 296 
hour creatinine clearance correlated negatively with all of these injury biomarkers at 16 hours (Supplementary 297 
Fig. 6). The urinary injury biomarkers uCysC, uClu and uNGAL were correlated with each other at 16 hours 298 
and these correlations were improved by normalisation to urinary creatinine (Supplementary Fig. 6 and 299 
Supplementary Table 1). 300 
 301 
3.8 Biomarker performance to diagnose functional AKI (AKIN 2/3) compared to healthy controls or 302 
NoAKI patients. 303 
The diagnostic utility of biomarkers in detecting functional AKI (AKIN 2/3) was assessed using ROC analysis 304 
[against biomarker concentrations obtained from the healthy controls (Fig. 6, Supplementary Table 2) or 305 
against no-AKI patients (Supplementary Table 2). At 16-24 hours sCysC, uCysC, uClu and uNGAL revealed 306 
a moderate diagnostic performance to diagnose functional AKI. Both absolute and normalised concentrations 307 
of these four biomarkers at 16-24 hours had AUC-ROC values ≥0.7 (Fig. 6). The 24hrMax (peak) and 308 
24hrAUC concentrations also showed similar diagnostic performance (Fig. 6). Sensitivity, specificity and cut-309 
off values for each of these biomarkers at 16 and 24 hours are shown in Supplementary Table 2.  310 
 311 
 312 
Fig. 6 Biomarker performance to diagnose AKI after paraquat poisoning  313 
AUC (±95% CI) as absolute (red) and normalised (blue) concentrations are shown for detection of AKI at 314 
different time points. The diagnostic performance in detection of functional AKI (AKIN stage ≥2) versus 315 
healthy controls is shown for 8, 16, 24 hours and maximum concentration within 24 hours, for each biomarker. 316 
  317 
 318 
 319 
The remaining biomarkers performed poorly in predicting functional AKI early (Supplementary Fig. 7). None of the 320 
urinary biomarkers distinguished AKIN stage 1 from no-AKI patients after paraquat (AUC≤0.5). 321 
 322 
3.9 Sensitivity analysis 323 
The sCr rise in paraquat poisoning may not be solely GFR related (Mohamed et al., 2015). As biomarker 324 
performances in this study were assessed using the AKIN consensus definition, a sensitivity analysis was conducted 325 
to assess the biomarker performance using an alternative sCysC definition (≥50% increase in sCysC). However, 326 
biomarker performance in detecting AKI based on either definition was similar (Table 4). 327 
 328 
Table Error! No text of specified style in document. Diagnostic performance of structural biomarkers (maximum 329 
concentration within first 24 hours) to diagnose functional AKI defined by sCr vs sCysC  330 
 331 
 
Urinary biomarkers 
AUC-ROC ((± 95% CI) 
AKIN sCr definition for 
functional-AKI† 
CysC definition for functional-
AKI‡ 
uClu 0.80 (0.69-0.96) 0.83 (0.66-0.92) 
uCysC 0.90 (0.80-1.00) 0.91 (0.81-0.99) 
uNGAL 0.84 (0.74-0.95) 0.84 (0.74-0.93) 
uB2M 0.82 (0.67-0.96) 0.82 (0.70-0.82) 
uKIM-1 0.53 (0.38-0.68) 0.53 (0.39-0.67) 
uIL18 0.54 (0.37-.76) 0.56 (0.38-0.78) 
uTFF3 0.75 (0.64-0.92) 0.78 (0.62-0.89) 
uOstP 0.54 (0.44-0.74) 0.60 (0.40-0.68) 
sCysC 0.81 (0.89-1.00) 0.94 (0.69-0.94) 
Diagnostic performance of each biomarker was assessed between biomarker concentrations in functional-AKI group 332 
(patients who developed functional AKI by either definition) versus healthy controls. † represents increase in serum 333 
creatinine (sCr) ≥ 100% (i.e. AKIN definition). ‡ represent increase in serum cystatin C (sCysC) ≥50% (CysC based 334 
AKI definition) 335 
 336 
4. Discussion 337 
This is the first comprehensive multi-centre clinical study to evaluate the diagnostic performance of all seven FDA 338 
and EMEA “qualified” AKI biomarkers as well as uNGAL, uOstP and uIL-18 to diagnose nephrotoxicity after 339 
paraquat poisoning. Uniquely, biomarker diagnostic performance was assessed against two markers of renal function 340 
sCr and sCysC and also independently using thresholds derived from healthy individuals from the same population 341 
groups. Only the biomarkers urinary biomarkers uCysC, uClu, and uNGAL revealed modest diagnostic performance 342 
for early detection of moderate to severe AKI as defined by ≥50% increase in sCysC, although uNGAL was increased 343 
for only 24 hours.  However, added clinical utility of these biomarkers to sCr is limited in moderate to severe paraquat 344 
poisoning where most patients died within 24-48 hours of toxicity and sCr predicted death independent of 345 
nephrotoxicity in this group (AUC-ROC=0.9). Since serum creatinine is readily available and a cost-effective test in 346 
less developed countries where paraquat poisoning is common, it will remain a prognostic marker of poor outcome. 347 
 348 
Poor biomarker performance in various clinical settings may be due to an imperfect gold standard used for defining 349 
AKI (Siew et al., 2011; Waikar et al., 2012).  While histopathological change has been used as the gold standard for 350 
AKI diagnosis in toxicity studies, biomarker performance in clinical studies has usually been assessed against loss 351 
of renal function, as demonstrated by an increase in sCr or sCysC.  In this study, we focussed on functional AKI as 352 
defined by a relative increase in sCr ≥100% sCr as it is widely used definition for assessing the biomarker 353 
performance (Waikar et al., 2012) or based on ≥ 50% sCysC (Nejat et al., 2010). Of patients meeting sCr definition 354 
of AKI (n=26), approximately 2/3 (n=19) showed a ≥50% rise in sCysC. Of 31 patients with <50% increase in sCysC, 355 
19 were classified as AKI based on sCr definition over-estimating AKI mainly due to increase in sCr by non-renal 356 
mechanisms (Mohamed et al., 2015). Defining AKI based on relative increase in sCysC may be more appropriate in 357 
paraquat poisoning (Fahim et al., 2013) and serum CysC is less affected by non-renal factors (Bagshaw and Bellomo, 358 
2010). Nevertheless, using ≥ 50% increase in sCysC to assess the biomarker performance also resulted in similar 359 
moderate diagnostic utility to AKIN definition in sensitivity analysis (Table 4). Validation of either sCr or sCysC as 360 
an appropriate surrogate marker of renal function awaits near real-time measurements of GFR.  361 
 362 
We also examined the use of the recently-proposed matrix definition of AKI, which incorporates both structural and 363 
functional biomarkers (Murray et al., 2014). This requires identification of appropriate biomarker cutoffs (Pickering 364 
and Endre, 2013b). Since such cutoffs are contextual and therefore unavailable in this first major study of AKI 365 
biomarkers in paraquat poisoning, we used structural biomarker cutoffs based on the 95th centile value in healthy 366 
volunteers to define AKI (Basu et al., 2014). While there were differences amongst the best performing urinary 367 
biomarkers (uCysC, uClu, uNGAL), overall this resulted in more patients being diagnosed as having structural (65%) 368 
than functional AKI (Figs. 4 & 5, Table 2). However, only subjects with functional AKI died (Fig. 5).  In the context 369 
of paraquat poisoning, renal damage alone (i.e., structural injury without significant loss of function) was not 370 
associated with death in any subjects. However, patient in this group had similar or higher serum paraquat level 371 
compare to functional AKI alone (i.e., functional AKI without structural injury). Nevertheless, the presence of 372 
functional AKI based on sCr or sCysC definition marked both more severe renal damage and also more severe 373 
systemic events leading to a fatal outcome. This contrasts with the performance of urinary KIM-1 and NGAL in other 374 
AKI settings, such as septic or haemorrhagic AKI, where biomarker positive, creatinine negative subjects are at 375 
comparable risk of mortality and dialysis to creatinine-positive biomarker negative subjects (Haase et al., 2011; 376 
Nickolas et al., 2012). Presumably these differences in predicting risk of serious outcomes reflect the role of the 377 
individual biomarkers in the specific pathways of injury involved. 378 
 379 
Since most renal injury biomarkers increased modestly and serum creatinine increased rapidly within 24 hours 380 
following moderate to severe paraquat poisoning, use of novel injury biomarkers to diagnose paraquat induced 381 
nephrotoxicity within first 2 days may be limited in clinical practice. Most patients in this group died within first 2 382 
days of admission and sCr predicted mortality independent of loss of GFR. Therefore, novel biomarkers may not 383 
offer added diagnostic value to sCr. Early death following paraquat toxicity is mainly due to multi-organ failure with 384 
circulatory collapse (Dinis-Oliveira et al., 2008; Gawarammana and Buckley, 2011). Thus, initiating dialysis or renal 385 
replacement therapy based on sCr level in this group of patients may not be appropriate especially in poor resource 386 
settings. Furthermore, use of haemodialysis or haemofiltration to enhance paraquat elimination is not supported by 387 
clinical evidence in moderate to severe paraquat poisoning (Eddleston et al., 2003; Koo et al., 2002; Suzuki et al., 388 
1993).  389 
 390 
Among dozens of renal biomarkers studied (including FDA and EMEA “qualified” biomarkers) only a few 391 
biomarkers predicted AKI, which suggests the biomarker are specific to an injury pathway.  Notably, uCysC, uClu 392 
and uNGAL were the most useful biomarkers in this study although their clinical significance in addition to sCr may 393 
be limited. Clusterin is expressed by dedifferentiated tubular epithelial cells as a cytoprotective agent following AKI 394 
(Rosenberg and Silkensen, 1995; Schwochau et al., 1998; Silkensen et al., 1997). Clusterin has a protective role 395 
against reactive oxygen species and its levels may increase in response to oxidative stress (Nath et al., 1994; 396 
Schwochau et al., 1998). Clusterin increases are therefore indirect evidence supporting oxidative stress as major 397 
mechanism of paraquat-mediated renal tubular toxicity (Nath et al., 1994; Rosenberg and Silkensen, 1995; 398 
Schwochau et al., 1998). In contrast, increases in uNGAL are indicative of a renal adaptation response to kidney 399 
injury (Mori et al., 2005). Upregulated NGAL may play a key role in preventing epithelial injury by scavenging free 400 
catalytic iron, the latter generating oxidative stress, by an anti-apoptotic effect, or by preserving N-cahedrin 401 
expression. NGAL also appear to upregulate heme oxygenase 1 which has anti-oxidant properties (Bolignano et al., 402 
2008; Mori et al., 2005). Increased levels of cystatin C (Bagshaw and Bellomo, 2010) following exposure to variety 403 
of nephrotoxins suggest that it serve as biomarkers of tubular injury and repairs. 404 
 405 
In a rodent paraquat model of AKI defined by histopathological changes, uKIM-1 and uCysC were the best predictive 406 
biomarkers within 16-24 hours, and uClu performed poorly (Table 5) (Wunnapuk et al., 2013). The results for uClu 407 
and uKIM-1 were reversed in our clinical subjects. Treatment is generally ineffective and unlikely to explain the 408 
difference from animal models since death is rapid and due to fulminant multi-organ failure within hours to days, 409 
and the creatinine rise may be due to predominantly non-renal effects.   The dissimilarities may also be due to 410 
difference in molecular forms of biomarkers between species (for example NGAL). NGAL in biological fluid is 411 
usually appears as monomeric and dimeric forms (Cai et al., 2010). NGAL monomeric form appears to be 412 
significantly correlated with tubular injury (Cai et al., 2010). However, most NGAL assays measure both forms. 413 
Sample handling and assay methods may also influence the results. The discrepancy may also be due to difference 414 
in defining AKI where animal study has used histopathology grading for defining AKI while human studies including 415 
this study uses sCr based AKI definition.  416 
 417 
 418 
Table 5 Comparative biomarker performance in predicting AKI within 24 hours in pre-clinical and clinical 419 
paraquat toxicity (Wunnapuk et al., 2013) 420 
 
Urinary biomarkers 
24 hour AUC-ROC (± 95% CI) 
Pre-clinical model 
(Wunnapuk et al., 2013) 
Clinical setting 
uKIM-1 0.98 (0.93-1.0) 0.63 (0.43-0.83) 
uCysC 0.88 (0.70-1.0) 0.85 (0.72-0.98) 
uNGAL 0.85 (0.72-0.98) 0.85 (0.72-0.98) 
uB2M 0.76 (0.54-0.98) 0.67 (0.47-0.88) 
sCysC 0.60 (0.40-0.80) 0.77 (0.61-0.93) 
uClu 0.54 (0.30-0.80) 0.70 (0.51-0.88) 
uIL18 - 0.68 (0.351-0.81) 
 421 
Subjects who survived beyond 3 days particularly following mild poisoning, urinary biomarkers generally predicted 422 
development of AKI, despite the limitations of the creatinine-based definitions already noted. Since absolute and 423 
normalised urinary CysC, clusterin and NGAL detect nephrotoxicity earlier than creatinine in this group (structural 424 
injury biomarker positive but functional biomarker negative) this may facilitate reno-protective intervention.  The 425 
good biomarker performance in both clinical and pre-clinical studies (Table 5) adds further support for the utility of 426 
uCysC and clusterin (Wunnapuk et al., 2013). Furthermore, patient who survived beyond three days following 427 
paraquat poisoning develop pulmonary fibrosis (Gawarammana and Buckley, 2011) and this group may benefit from 428 
dialysis if started early. Clearly, further studies with long-term follow-up assessment are warranted to explore the 429 
utility of structural injury biomarkers in mild paraquat and its long term effects. 430 
 431 
4.1 Strengths and limitations 432 
Although this study has some notable strengths including being multicentre and of a larger size than previous paraquat 433 
nephrotoxicity studies and the exploration of a broad range of biomarkers at multiple time points, it also has 434 
limitations. These include the absence of direct measurement of GFR and the absence of absolute baseline functional 435 
or damage biomarker levels. Since a sensitivity analysis performed using some of the subjects included in this study 436 
showed that different baseline estimates did not result in under or over reporting of AKI incidence  in paraquat 437 
poisoned patients (Fahim et al., 2013) and baseline sCysC was similar, this limitation is of less concern.  438 
 439 
5. Conclusions 440 
Serum cystatin C, urinary cystatin C, clusterin, and to a lesser extent NGAL showed modest diagnostic performance 441 
in moderate to severe paraquat poisoning.  Since most patients died in this group and sCr predicted mortality 442 
independent of nephrotoxicity, clinical utility of renal injury biomarkers in addition to sCr is limited. Serum cystatin 443 
C should be used to diagnose AKI in paraquat poisoning. Increase in specific injury biomarkers identified mechanistic 444 
pathways of nephrotoxicity in proximal tubules. Use of structural injury biomarkers within 16-24 hours of ingestion 445 
may guide early intervention for reno-protection in mild paraquat poisoning. Point-of-care biomarker detection 446 
should accelerate early intervention in these groups of patients in rural Asia.  447 
 448 
Conflict of interest statement 449 
We declare there is no conflict of interest. 450 
 451 
Acknowledgments 452 
We thank the physicians, directors, medical and nursing staff of the study hospitals and SACTRC staff for their 453 
support. We also thank all the patients who took part in the study. The project was funded by NHMRC project grant 454 
1011772. FM received an Endeavour Postgraduate Scholarship from the Australian Government (2241_2011). 455 
Funding body had no role in the design and execution of this study or interpretation of the data or decision to submit 456 
the manuscript. 457 
  458 
Appendix A. Supplementary data 459 
 460 
 461 
Supplementary Fig. 1. Scatter plots of urinary biomarkers at 16 hours from the main cohort according to 462 
AKIN staging and highest biomarker concentrations in patients from cross sectional cohort (CSC).  463 
Thirty-one patients were excluded from the main cohort as they provided only one blood or urine sample; some only 464 
provided either a blood or urine sample. These graphs show 24-hour maximum biomarker concentration profiles in 465 
CSC were similar to that of patients in the main cohort. The solid blue symbol depicts biomarker concentrations in 466 
patients who died.   467 
 468 
  469 
 470 
Supplementary Fig. 2. Serial biomarker profiles (normalised to urinary creatinine) following paraquat poisoning, 471 
relative to development of AKI 472 
Normalised biomarker concentrations of uAlb, uβ2M, uIL-18, uOstP and uTFF3 are plotted for each patient (dashed 473 
line). Blue dashed lines depict patients who developed AKI stage 2 and other patients in this group represent AKI 474 
stage 3. The dark bolded lines represent median (±IQR) changes in each group (black No-AKI group; green AKI 475 
stage 1 group, red AKI >=2 group). The shaded area illustrates the normal range based on respective biomarker 476 
concentration measurements in healthy individuals (dark grey: 5th to 75th centiles; light grey: 75th to 95th centiles) 477 
 478 
 479 
Supplementary Fig. 3. Absolute biomarker concentration profiles following paraquat poisoning.  480 
Individual patient’s absolute concentrations of uCysC, uClu, uKIM-1 and uNGAL are shown (dashed lines). Blue 481 
dashed lines depict patients who developed AKI stage 2 and other patients in this group represent AKI stage 3. The 482 
dark bolded line in each graph represents the median (± IQR) change in each group (green line-No-AKI group; 483 
purple line-AKI stage 1 group, red line-AKI≥2 group). The grey shaded area illustrates the normal range based on 484 
respective biomarkers measured in healthy individuals (dark grey area-5th to 75th centiles; light grey area-75th to 485 
95th centiles of the normal range). 486 
 487 
Supplementary Fig. 4. Absolute serial biomarker profiles following paraquat poisoning, relative to 488 
development of AKI.  489 
Absolute biomarker concentrations of uAlb, uβ2M, uIL-18, uOstP and uTFF3 are plotted for each patient (dashed 490 
line). Blue dashed lines depict patients who developed AKI stage 2 and other patients in this group represent AKI 491 
stage 3. The dark bolded lines represent median (±IQR) changes in each group (black No-AKI group; green AKI 492 
stage 1 group, red AKI >=2 group). The shaded area illustrates the normal range based on respective biomarker 493 
concentration measurements in healthy individuals (dark grey: 5th to 75th centiles; light grey: 75th to 95th centiles) 494 
 495 
 496 
Supplementary Fig. 5. Peak urine and serum biomarker concentration versus maximum change in sCr 497 
The maximum 24 hour absolute sCysC and both absolute and normalised concentrations of uCysC, uClu and uNGAL 498 
are shown. The scatter plot displays maximum 24 hour peak concentrations of biomarker against 24 hour peak sCr 499 
to baseline sCr ratio. The dotted lines show 95% CI of the slope. The slope of each relationship illustrates the 500 
enhancement associated with normalising each biomarker as a function of relative change in serum creatinine.  501 
 502 
  503 
Supplementary Table 1. Correlations (Spearman) among injury biomarkers after paraquat poisoning  504 
 505 
 Absolute biomarker concentrations Normalised biomarker 
concentrations 
 uClu uCysC uClu uCysC 
16 hour biomarker concentrations 
uCysC 0.89*  0.90*  
uNGAL 0.31 0.46* 0.54* 0.70* 
24hrMax concentrations† 
uCysC 0.76*  0.83*  
uNGAL 0.23 0.58* 0.44* 0.73* 
24hrAUC‡ 
uCysC 0.83*  0.89*  
uNGAL 0.37* 0.61* 0.46* 0.66* 
†Peak biomarker concentration within 24 hours of ingestion. ‡ Total area under the concentration curve at 24 hours. 506 
* p < 0.05 (significant correlation) 507 
  508 
 509 
Supplementary Fig. 6. Correlations amongst injury and functional biomarkers at 16 hours 510 
The correlation (Spearman) plots depict injury biomarkers (uClu, uCysC and uNGAL) vs sCr (Fig. a to d), sCysC 511 
(Fig. e to g) and 24 hour apparent creatinine clearance (Fig. h to k). Positive correlations were obtained for injury 512 
biomarkers compared to sCr; negative correlations were seen with 24 hour creatinine clearance. Serum CysC was 513 
weakly correlated with injury biomarkers. 514 
  515 
Supplementary Table 2: Diagnostic characteristics of biomarkers in early diagnosis of functional-AKI (stage 2/3) in paraquat poisoning.  516 
AKI≥2 versus healthy individuals AKI≥2 versus all non-AKI patient controls 
Biomarker
s 
AUC-ROC 
(95% CI) 
p Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Cut-off AUC-ROC 
(95% CI) 
P Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Cut-off 
16 hours post ingestion (absolute concentration) 16 hours post ingestion (absolute concentration) 
sCysC 
(mg/l) 
0.66 
(0.49-0.83) 
<0.05 68 (43-87) 52 (37-66) >0.84  0.76  
(0.59-0.94) 
<0.05 74 (48-91) 78 (40-97) > 0.82  
uClu 
(ng/ml) 
0.69  
(0.49-0.88) 
<0.05 69 (41-89) 60 (43-74) >266  0.79  
(0.61-0.98) 
<0.05 75 (48-93) 71 (29-96) >144  
uCysC 
(ng/ml) 
0.79  
(0.62-0.96) 
<0.001 73 (44-92) 73 (57-86) >46  0.82  
(0.63 -1.00) 
<0.05 73 (45-92) 83 (36-100) > 53  
uNGAL 
(ng/ml) 
0.79  
(0.66-0.9) 
<0.001 80 (52-74) 74 (59-86) >23 0.66  
(0.37-0.94) 
>0.05 67 (38-88) 50 (12-88) > 29  
24 hours post ingestion (absolute concentration) 24 hours post ingestion (absolute concentration) 
sCysC 
(mg/l) 
0.73  
(0.58-0.88) 
<0.01 68 (45-86) 72 (58-84) >0.88 0.77  
(0.61-0.93) 
<0.05 68 (45-86) 70 (35-93) > 0.86  
uClu 
(ng/ml) 
0.61  
(0.45-0.78) 
>0.05 67 (45-84) 67 (50-80) >280 0.70  
(0.51-0.88) 
>0.05 70 (49-87) 70 (35-93) > 194  
uCysC 
(ng/ml) 
0.81  
(0.68-0.93) 
<0.0001 70 (47-87) 70 (54-84) >45 0.85  
(0.72-0.98) 
<0.01 74 (52-90) 70 (35-93) > 41  
uNGAL 
(ng/ml) 
0.78  
(0.65-0.90) 
<0.001 74 (52-90) 74 (58-86) >24 0.85  
(0.72-0.98) 
<0.01 78 (56-92) 70 (35-93) > 15 
Comparisons were made between stage 2/3 (AKI ≥2) vs healthy controls and AKI ≥2 vs no-AKI patient controls. Data are presented only for the best performing 517 
biomarkers to diagnose AKI.518 
34 
 
 519 
 520 
Supplementary Fig. 7.  Biomarker performances to diagnose AKI following paraquat poisoning  521 
AUC (±95% CI) as absolute (red) and normalised (blue) concentrations are shown for detection of AKI at 16 522 
and 24 hours. Diagnostic performance was assessed between patients in functional AKI (AKIN stage ≥2) group 523 
and healthy controls at each time point (* p<0.05).  524 
  525 
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